Current status and advances in transjugular intrahepatic portosystemic shunt in treatment of refractory ascites due to portal hypertension
10.3969/j.issn.1001-5256.2023.07.004
- VernacularTitle:经颈静脉肝内门体分流术治疗门静脉高压性顽固性腹水的现状及进展
- Author:
Hongliang WANG
1
,
2
,
3
;
Yuelin ZHANG
1
,
2
,
3
;
Kaibing WANG
1
,
2
,
3
;
Tanyang ZHOU
1
,
2
,
3
;
Guanhui ZHOU
1
,
2
,
3
;
Junhui SUN
1
,
2
,
3
Author Information
1. Intervention Center of Hepatobiliary and Pancreatic Diseases
2. Zhejiang Provincial Clinical Medical Research Center of Hepatobiliary and Pancreatic Diseases, Zhejiang Provincial Research Center of Diagnosis and Treatment Techniques for Severe Hepatobiliary Diseases (Transplantation)
3. The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
- Publication Type:Discussions by Experts
- Keywords:
Portasystemic Shunt, Transjugular Intrahepatic;
Liver Cirrhosis;
Portal Hypertension;
Ascites
- From:
Journal of Clinical Hepatology
2023;39(7):1535-1540
- CountryChina
- Language:Chinese
-
Abstract:
Refractory ascites is one of the common complications of portal hypertension in decompensated liver cirrhosis and is characterized by extremely poor prognosis and high mortality rate. Transjugular intrahepatic portosystemic shunt (TIPS) is recommended by several international and national guidelines as one of the treatment methods after failure of large volume paracentesis combined protein infusion therapy. TIPS can effectively control the recurrence of ascites, but it can increase the risk of hepatic encephalopathy, and there are still controversies over whether it can prolong survival time. With a deeper understanding of TIPS, the maturity of surgical techniques, and the update of stent materials, it is urgent to reevaluate the position of TIPS in the treatment of refractory ascites due to portal hypertension. This article reviews the current status and advances in TIPS for the treatment of refractory ascites due to portal hypertension.
